April 17, 2020
The Best and Leading Candidate Vaccines Revealed to Fight COVID-19
The continuing outbreak of the COVID-19 affecting millions of lives already had triggered many scientists to find the best cure and that includes studying the best candidate vaccines available.
They are now testing different nucleic acid (DNA and RNA) as well as virus-like particles.
Due to the continuing outbreak of the pandemic Novel Corona Virus 2019 (COVID-19), that affects millions of people worldwide today, scientific and medical experts are finding the best cure from the different available candidate vaccines.
As published online through Gulfnews.com, the World Health Organization (WHO) is currently monitoring the study of the leading vaccines that can potential defeat the virus. The WHO is the main organization with the responsibility of searching for the most effective vaccine to prevent the outbreak and eliminate COVID-19.
Based on the assessment, they study the potential vaccines to their capacity in defeating the target pathogens that cause the spreading of the diseases. Furthermore, the study determines the possibility of their relationship to the newest viruses that can infect the human body.
According from the reports online, the 5 leading candidate vaccines include the following:
- Ad5-nCoV [CanSino Biologicals]
- mRNA-1273 [Moderna]
- INO-4800 [Inovio]
- Pathogen-specific aAPC [Shenzhen Geno-Immune Medical Institute]
- LV-SMENP-DC [Shenzhen Geno-Immune Medical Institute]
These potential vaccines had shown great signs of effectiveness and so they need to exert more effort to study them thoroughly. From the estimate figure on how much it cost to invest and develop such vaccines, it is nearly $2 billion as detailed by the Coalition for Epidemic Preparedness Innovations (CEPI) experts.
According to the published news also related to this issue, the United Kingdom already allocated 20 million pounds for the development procedure.
Currently, over 70 different potential vaccines are under study, but the listed 5 above are the leading candidates.
The Ad5-nCoV is under the monitoring of Hong Kong’s Cansino Bio and Beijing Institute of Biotechnology. They already plan to schedule the clinical tests (phase 2) with the other genetic engineered candidate vaccine in Mainland.
As for the other leading candidate mRNA-1273, the Moderna pharmaceutical in Massachusetts already received the green light of the regulator to begin the clinical test for human last March. While the INO-4800 of the Inovio pharmaceuticals, it began its clinical test for human this April (last week), according to the dailymail.co.uk.
The WHO is likewise monitoring the developments of the remaining 67 vaccines as candidate to fight the pandemic virus. The pre-clinical assessment came from various school institutions like the University of Queensland (Australia), Osaka University (Japan), Imperial College and University of Oxford (London).
Despite the efforts shown by the group of experts in developing the best vaccines, many believe that it may still take months or years before they can possible eliminate the virus completely.
However, the good important thing is that the world is trying to control the outbreak.
To date, countries like the US, South Korea and China are already scheduling the clinical tests for healthy human beings this month. The results of the tests play a huge role in the process of manufacturing the approved vaccines and cure the millions of infected patients worldwide.